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Abstract: HIV-associated sensory neuropathy (HIV-SN) is the most frequent manifestation of HIV
disease. It often presents with significant neuropathic pain and is associated with
previous exposure to neurotoxic nucleoside reverse transcriptase inhibitors. However,
HIV-SN prevalence remains high even in resource-rich settings where these drugs are
no longer used. Previous evidence suggests that exposure to indinavir, a protease
inhibitor commonly used in antiretroviral therapy, may link to elevated HIV-SN risk.
Here we investigated whether indinavir treatment was associated with the development
of a "dying back" axonal neuropathy and changes in pain-relevant limb withdrawal and
thigmotactic behaviours. Following two intravenous injections of indinavir (50 mg/kg, 4
days apart), adult rats developed hindpaw mechanical hypersensitivity, which peaked
around 2 weeks post first injection (44% reduction from baseline). At this time, animals
also had 1) significantly changed thigmotactic behaviour (62% reduction in central
zone entries) comparing to the controls and 2) a significant reduction (45%) in hindpaw
intraepidermal nerve fibre density. Treatment with gabapentin, but not amitriptyline,
was associated with a complete attenuation of hindpaw mechanical hypersensitivity
observed with indinavir treatment. Furthermore, we found a small but significant
increase in microglia with the effector morphology in the lumbar spinal dorsal horn in
indinavir-treated animals, coupled with significantly increased expression of phospho-
p38 in microglia. In summary, we have reported neuropathic pain-related sensory and
behavioural changes accompanied by a significant loss of hindpaw skin sensory
innervation in a rat model of indinavir-induced peripheral neuropathy that is suitable for
further pathophysiological investigation and preclinical evaluation of novel analgesics.
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Dear Prof Keefe, 
 
We are submitting our revised manuscript characterizing a rodent model of HIV protease 
inhibitor indinavir induced peripheral neuropathy.  
 
We are pleased to hear that you, the Section Editor, and the reviewer #1 have considered that 
our manuscript is suitable for publication in PAIN pending minor revisions. We have 
addressed the reviewer’s minor concerns (highlighted in red color in the manuscript) as 
follows: 
 
1. Concern 1: “The authors should indicate the concentrations of each antibodies they used.”  
Response: We have included antibody concentrations in the result section as suggested by the 
reviewer (page 8, second paragraph; page 9, second paragraph). 
 
2. Concern 2: “There are also some spelling mistakes that need to be fix. For example, in the 
abstract: phospho-p38 instead of "phopspho-p38", p12 line 3-4 cold hypersensitivity instead 
of mechanical hypersensitivity.” 
Response: We have corrected the spelling mistakes (page 2, line 16; page 12, line 3). 
 
We feel that the above changes have addressed the minor concerns of the reviewer. We thank 
you for considering our submission for publication in Pain. 
 
 
Yours Sincerely, 
 
 
 
Dr. Wenlong Huang 
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Abstract 
 
HIV-associated sensory neuropathy (HIV-SN) is the most frequent manifestation of HIV 
disease. It often presents with significant neuropathic pain and is associated with previous 
exposure to neurotoxic nucleoside reverse transcriptase inhibitors. However, HIV-SN 
prevalence remains high even in resource-rich settings where these drugs are no longer used. 
Previous evidence suggests that exposure to indinavir, a protease inhibitor commonly used in 
antiretroviral therapy, may link to elevated HIV-SN risk. Here we investigated whether 
indinavir treatment was associated with the development of a “dying back” axonal neuropathy 
and changes in pain-relevant limb withdrawal and thigmotactic behaviours. Following two 
intravenous injections of indinavir (50 mg/kg, 4 days apart), adult rats developed hindpaw 
mechanical hypersensitivity, which peaked around 2 weeks post first injection (44% reduction 
from baseline). At this time, animals also had 1) significantly changed thigmotactic behaviour 
(62% reduction in central zone entries) comparing to the controls and 2) a significant 
reduction (45%) in hindpaw intraepidermal nerve fibre density. Treatment with gabapentin, 
but not amitriptyline, was associated with a complete attenuation of hindpaw mechanical 
hypersensitivity observed with indinavir treatment. Furthermore, we found a small but 
significant increase in microglia with the effector morphology in the lumbar spinal dorsal 
horn in indinavir-treated animals, coupled with significantly increased expression of phospho-
p38 in microglia. In summary, we have reported neuropathic pain-related sensory and 
behavioural changes accompanied by a significant loss of hindpaw skin sensory innervation in 
a rat model of indinavir-induced peripheral neuropathy that is suitable for further 
pathophysiological investigation and preclinical evaluation of novel analgesics. 
 
 
Abstract
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Abstract 
HIV-associated sensory neuropathy (HIV-SN) is the most frequent manifestation of HIV disease. It 
often presents with significant neuropathic pain and is associated with previous exposure to 
neurotoxic nucleoside reverse transcriptase inhibitors. However, HIV-SN prevalence remains high 
even in resource-rich settings where these drugs are no longer used. Previous evidence suggests that 
exposure to indinavir, a protease inhibitor commonly used in antiretroviral therapy, may link to 
elevated HIV-SN risk. Here we investigated whether indinavir treatment was associated with the 
development of a “dying back” axonal neuropathy and changes in pain-relevant limb withdrawal 
and thigmotactic behaviours. Following two intravenous injections of indinavir (50 mg/kg, 4 days 
apart), adult rats developed hindpaw mechanical hypersensitivity, which peaked around 2 weeks 
post first injection (44% reduction from baseline). At this time, animals also had 1) significantly 
changed thigmotactic behaviour (62% reduction in central zone entries) comparing to the controls 
and 2) a significant reduction (45%) in hindpaw intraepidermal nerve fibre density. Treatment with 
gabapentin, but not amitriptyline, was associated with a complete attenuation of hindpaw 
mechanical hypersensitivity observed with indinavir treatment. Furthermore, we found a small but 
significant increase in microglia with the effector morphology in the lumbar spinal dorsal horn in 
indinavir-treated animals, coupled with significantly increased expression of phospho-p38 in 
microglia. In summary, we have reported neuropathic pain-related sensory and behavioural changes 
accompanied by a significant loss of hindpaw skin sensory innervation in a rat model of indinavir-
induced peripheral neuropathy that is suitable for further pathophysiological investigation and 
preclinical evaluation of novel analgesics. 
 
(Word count = 250) 
Key words: HIV; peripheral; neuropathy; neuropathic pain; rat; indinavir; thigmotaxis
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Introduction 
 
HIV-associated sensory neuropathy (HIV-SN) is the most frequent neurological manifestation of 
HIV disease and is seen in 40-50% of patients whose HIV disease is otherwise well controlled by 
antiretroviral therapy (ART) [22; 24; 47]. HIV-SN is a distal symmetrical, predominantly sensory, 
polyneuropathy. The symptoms of HIV-SN present with a characteristic gloves and socks 
distribution and it is associated with significant neuropathic pain [1; 12; 31; 45; 48]. HIV-SN has 
been hither to thought to result from two clinically indistinguishable neuropathies with distinct 
pathogenesis: a distal axonal degeneration caused by interaction of sensory neurones with HIV 
proteins e.g. HIV glycoprotein gp120 [3; 16; 23; 32; 38; 47; 49] and ART-induced toxic neuropathy 
associated with nucleoside reverse transcriptase inhibitors (NRTIs) [22; 24; 50].  
 
Since NRTI introduction, the morbidity and mortality of HIV infection have been markedly reduced 
[22]. Whilst certain d-NRTIs such as zalcitabine (ddC) and stavudine (d4T) [18; 50] are 
undoubtedly neurotoxic, the prevalence of HIV-SN in resource-rich settings did not decline in 
patients who have never been exposed to these drugs [9; 22], suggesting that alternative or 
additional factors may underlie HIV-SN in the clinical setting. Protease inhibitors are regularly used 
a part of combinational ART. A number of studies have linked exposure to protease inhibitor 
medication to HIV-SN risk [8; 29; 39; 46], including a demonstration of indinavir potentiating the 
neurotoxicity of HIV in a transgenic rat model using cultured dorsal root ganglia (DRG) [39][52]. 
Thus, HIV-infected DRG cultures exposed to indinavir showed significant neuronal atrophy, neurite 
retraction, and process loss, compared with controls. However, this association between protease 
inhibitors and HIV-SN also remains far from clear. A review of adults initiating combinational 
ART in AIDS Clinical Trials Group (ACTG) studies found HIV-SN risk was only increased by 
protease inhibitor use if the patient was also using at least one neurotoxic d-NRTI [13]. Further 
analysis of patients involved in the US-based CHARTER (CNS HIV Anti-Retroviral Treatment 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 4 
Effects Research) cohort found small, if any, independent effect of protease inhibitor exposure on 
HIV-SN risk [11].  
 
Rat models have been used to understand the pathogenesis of HIV-SN and to develop novel 
therapeutics for HIV-SN [17; 19-21; 23; 49-52]. Here we hypothesised that systemic indinavir 
treatment in rats would produce signs of peripheral neuropathy and neuropathic pain-like 
behaviours. Initially, we validated the approach in behavioural studies, which showed that 
indinavir-treated rats developed hindpaw mechanical and cold, but not heat, hypersensitivity and 
pain-related aberrations in complex, ethologically relevant thigmotactic behaviour [17; 49; 50]. We 
then elucidated the clinical diagnostic feature of a length dependent “dying back” small fibre axonal 
neuropathy by demonstrating loss of epidermal innervation following indinavir treatment.  
 
(Word count = 435) 
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Materials and Methods 
 
Ethical statement 
Animal experiments were conducted in accordance with United Kingdom law (Animal Scientific 
Procedures Act 1986; Project License PPL70/7162) and IASP guidelines [54]. The ARRIVE 
reporting guidelines were followed [25]. An ARRIVE checklist is provided in the supplementary 
materials. 
 
Experimental animals 
Temperature-controlled standard rat IVC cages (21C, 2-3 per cage) with corncob bedding were 
used for housing the animals (male adult Wistar rats; 200–300 g; Charles River, UK). We did not 
use environment enrichment. Rats were kept on a 12:12 h light–dark cycle. Normal rat chow (RM1 
pellets; Special Diet Services, Essex, UK) and tap water ad libitum were provided. Animals were 
allowed to acclimatise for 48 h following delivery.  
 
Study design  
In order to reduce experimental bias, we followed major domains of Good Laboratory Practice [30; 
43] (Supplementary Table 1). Behavioural experiments were carried out in the light phase in the 
behavioural laboratory, and intravenous (i.v.) and intraperitoneal (i.p.) injection procedures were 
conducted in the surgical laboratory, all at Imperial College London (Chelsea & Westminster 
Campus). We used batches of subset experiments (normally 2-3 animals per group) for thigmotaxis. 
Sequences of A-B-C then C-B-A (letters assigned to mask the cage labels during testing) were used 
to select animals.            
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Indinavir administration 
Under general anaesthesia [1-2% isoflurane (Abbott, UK) in O2 and N2O ratio 1:1], indinavir (0.5 
ml; 50 mg/kg in sterile saline; donated by Pfizer Ltd.) was administered via a tail vein. Four days 
later, a second injection of indinavir was carried out at the same dose and volume. Control animals 
were given sterile saline at equivalent volumes. Previous animal data with other antiretroviral drugs 
have shown that oral gavage and i.v. routes result in comparable nocifensive behavioural profiles 
[19]. Therefore, we decided to use the i.v. route, which would minimise handling stress caused by 
oral gavage. The dose and treatment regime were chosen based on previous studies with ddC and 
d4T [17; 19; 50].  
 
Hindpaw mechanical hypersensitivity 
The procedure to assess hindpaw withdrawal to mechanical stimuli was the same as in our previous 
study [50]. An electronic “von Frey” device (0.5 mm2 probe tip area; Somedic Sales AB, Sweden) 
was used to measure the withdrawal threshold in response to punctate static mechanical stimulation. 
We carried out 2 habituation sessions (40-50 min each) and then 2 baseline tests. Animals were 
placed in plexiglass boxes (23 x 18 x 14 cm) with 0.8 cm diameter mesh flooring for 
acclimatisation. When exploratory behaviour ceased, the probe was used to deliver an increasing 
force (rate of 8-15 g/s) and was applied to the mid-plantar until the animal actively withdrew the 
paw. This was repeated 4 times at 1 min interval between each application.  
 
Hindpaw cold hypersensitivity 
Cold hypersensitivity was assessed using the acetone drop method [5]. Animals were placed in 
plexiglass boxes (23 x 18 x 14 cm) with 0.8 cm diameter mesh flooring and allowed to acclimatise 
for 15 min or until exploratory behaviour ceased. The cooling stimulus was a single bubble of 
acetone applied to the mid plantar surface of each hindpaw delivered from the tip of a 1 ml syringe. 
A positive response was recorded when the rat withdrew its paw following the acetone application. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 7 
For each measurement, five acetone drop applications were delivered and a mean limb withdrawal 
rate calculated. At least 3 min were allowed to elapse between each test. 
 
Hindpaw response to noxious heat 
Hypersensitivity to noxious heat was assessed by measuring the limb withdrawal time following 
application of an infrared heat stimulus (Plantar test, Ugo Basile, Italy, Hargreaves et al., 1988). 
Briefly, animals were placed in a clear plexiglass box (23 x 18 x 14 cm) with a dry glass floor and 
allowed to acclimatise for 15 min or until exploratory behaviour ceased. A focused infrared beam 
(46C, wavelength 50 nm) was delivered to the plantar surface of the hindpaw. The paw withdrawal 
latency (s) to this stimulus was tested three times at intervals of not less than 3 min and a mean 
withdrawal latency calculated. To avoid thermal injury, an automatic cut-off time of 21 s was set. 
 
Thigmotactic behaviour  
The rationale of thigmotaxis as a predator avoidance ethologically-relevant behavioural outcome 
measure in rodent pain studies has been previously described [17]. At PID 15, the rats were 
introduced for the first time to the 100 x 100 cm open field arena, which was lit to a light intensity 
of 12 lux. Locomotor activity was then recorded for 15 min using a high-sensitivity Sanyo camera 
(VCB 3372, Japan). EthoVision software (v.4.1, Tracksys Ltd., UK) was used to track the 
movement of animals in the arena, and to calculate the frequency of entry and time spent in the 
virtual central zone (40 x 40 cm) as well as the total distance travelled in the whole open field arena.  
 
Pharmacological validation 
Animals received i.p. injections of either analgesic drugs or vehicle solutions twice per day (b.d.) 
between PID 12 and 15, during which the hindpaw withdrawal thresholds were measured in 
response to punctate static mechanical stimulation once per day at 1.5–2 h after the first injection. 
We chose to test gabapentin (0.5 ml; 30 mg/kg in sterile saline; a gift from Pfizer Ltd.) and 
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 8 
amitriptyline (0.5 ml; 10 mg/kg in sterile saline; Sigma, UK;), which was based on previous studies 
and clinical trials [15; 41; 50]. 
 
Immunohistochemistry and quantitative analysis 
The procedures for tissue processing, immunohistochemistry and quantitative analysis were the 
same as previously described [17]. Briefly, at PID 14, we terminally anaesthetised some animals 
with sodium pentobarbital, and then transcardially perfused them using 4% paraformaldehyde. 
Following perfusion, we removed L5 spinal cord, L5 DRGs, and glabrous hindpaw skin, and then 
post fixed the tissue in 4% paraformaldehyde overnight. We then used 30% sucrose in PBS to 
cryoprotect the tissue for 72 h. Cryostat sections of OCT-embedded tissue were cut  (spinal cords at 
20 µm, DRG at 10 µm, skin at 14 µm) and collected on superfrost slides. Sections were incubated 
with 10% normal donkey serum for 60 min followed by overnight incubation with the following 
appropriate primary antibodies: rabbit anti-GFAP (1:1000; Dako, UK), rabbit anti-CGRP (1:2000; 
Sigma, UK), rabbit anti-Iba1 (1:1000; WAKO, Japan), rabbit PGP 9.5 (1:1000; Ultraclone Ltd., 
UK). Following 3 PBS washes, sections were incubated with appropriate secondary donkey anti-
rabbit Cy3 or FITC antibodies (1: 400; Stratech, UK) for 2 h. Biotin-conjugated isolectin B4 (IB4; 
0.5 mg/mL used at 1:50; Sigma, UK) and ExAvidin–fluorescein isothiocyanate (1:400; Sigma, UK) 
were used to detect nonpeptidergic C-fibres in the skin. Following 3 PBS washes, slides were 
cover-slipped with Vectashield mounting medium (Vector Laboratories, UK) and visualised under a 
Zeiss Axioplan 2 fluorescent microscope (Zeiss, U.K). 
 
The experimenter who performed quantitative analysis was blind to treatment groups. We used 4 
areas (50,000 µm2 each) in the superficial dorsal horn and 4 areas (1,500 µm2 each) in the DRG 
from 5–7 randomly selected sections per rat to quantitatively analyse Iba1 immunoreactive cell 
numbers. We classified Iba1 immunoreactive cells in the dorsal horn as having “effector” 
morphology when their process lengths were less than double the soma diameter. In contrast, we 
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classified Iba1 immunoreactive cells in the dorsal horn as having “resting” morphology when their 
process lengths were double the soma diameter. We used 6–8 randomly selected sections from L5 
dorsal horn per rat to analyse the intensity of GFAP immunoreactivity that was expressed in 
arbitrary units. We also measured the intensity of IB4 or CGRP immunoreactivity in laminae I and 
II. We used 6-8 DRG sections per rat to analyse IB4/CGRP expression. The number of IB4+ or 
CGRP+ cells was expressed a percentage of the total DRG cells. We only sampled DRG cells with 
visible nucleus and distinctly delineated borders. We live counted PGP9.5+ epidermal fibres at 40X 
objective magnification using the method described previously [28]. Thus, we only counted single 
fibres crossing the dermal-epidermal junction without secondary branches. Then the epidermal 
innervation density (IENFD/mm) was calculated based on the epidermis length measure by Image J 
software 1.45 (NIH). 
 
For investigating the expression of phospho-p38 (pp-38) in microglia, spinal cord sections were 
incubated overnight with the primary antibody rabbit anti-pp-38 (1:100; Cell Signalling, USA), 
which was then amplified using a TSATM Biotin System (Perkin Elmer, UK). The slides were then 
incubated with rabbit anti-Iba1 (1:1000) primary antibody, followed by corresponding secondary 
antibody (1:400) solution. Double staining images were taken at 20x objective magnification using 
a Leica DM R light microscope (Leica Microsystems, Germany). The number of cells 
immunoreactive for both pp-38 and Iba1 in the superficial dorsal horn was counted using Photoshop 
CS5 (Adobe, USA) and expressed as a percentage of Iba1 immunoreactive cells.  
 
Statistics 
Statistical analysis for the behavioural study data was performed using IBM SPSS Statistics Version 
23. For the mechanical, cold, and heat hypersensitivity as well as the pharmacological validation 
study, two-way ANOVA was used to examine the main effects of treatments, times, and interaction 
between treatments and times where appropriate. The Tukey-Kramer post hoc multi-comparison 
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adjustment was used to determine if there was any significant difference between treatment groups, 
i.e. vehicle vs indinavir, and saline vs gabapentin or amitriptyline. For the thigmotaxis study, one-
way ANOVA followed by Tukey-Kramer post hoc multi-comparison adjustment was used to 
evaluate if there was a main treatment effect and if significant differences between groups 
(indinavir, vehicle and naive) existed. In addition, we included the total distance moved in the open 
field arena as a secondary outcome for the thigmotactic analysis. The box and scatter plots for the 
thigmotaxis data were made using OriginPro 2016 (OriginLab, USA). All measurements are 
expressed as mean value±standard error of the mean (SEM) in the Result section. In addition, 
behavioural data are presented using 95% confidence levels in the Supplementary Table 3. P<0.05 
was considered as statistically significant. 
 
For histological analysis, differences between vehicle- and indinavir-treated animals were 
determined using a non-parametric test, the Wilcoxon-Mann-Whitney Test. We report our data as 
mean values±SEM and consider P<0.05 as statistically significant.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 11 
Results 
 
No animals were excluded from the current study according to the inclusion and exclusion criteria 
set in the Supplementary Table 1. A summary of group sizes and primary outcome measures is in 
Supplementary Table 2.  
 
Indinavir treatment results in hindpaw hypersensitivity to mechanical stimuli 
To investigate the effect of indinavir treatment in mechanical sensitivity of rats we tested animals 
that have and have not received the drug for up to 42 days using an electronic ‘von Frey’ device. 
We observed that rats treated with indinavir (n=6) developed bilateral hindpaw mechanical 
hypersensitivity, which occurred from PID 4 and reached a peak at PID 14 (Figure 1). Withdrawal 
thresholds were changed from the baseline at -26%, -33%, -39%, -44%, -36% and -26% for PID 4, 
7, 11, 14, 28 and 35 respectively. Here, we did not observe significant difference in mechanical 
hypersensitivity between the left and right hindpaws (data not shown). Therefore, we pooled the 
withdrawal thresholds from both hindpaws. The hindpaw mechanical hypersensitivity following 
indinavir treatment was maintained until PID 42, and then the thresholds showed a trend returning 
to the baseline. The statistical analysis revealed significant effects of treatments, times and the 
interaction between treatments and times on hindpaw mechanical hypersensitivity development (for 
treatment: P=0.0001, df=1, F=944.05; for time: P=0.0001, df=7, F=62.170; for interaction between 
treatment and time: P=0.0001, df=7, F=55.844). 
 
Indinavir treatment results in hindpaw hypersensitivity to cold stimuli 
To examine if indinavir treatment could lead to changes in cold sensitivity we tested treated versus 
untreated animals using the acetone test. We observed that rats treated with indinavir (n=6) 
developed bilateral hindpaw cold hypersensitivity, which occurred from PID 6, plateaued between 
PID 13 and 31, and then maintained between PID 41 and 45 (Figure 2). Mean percentage changes 
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of the %response to cold stimuli from the baseline were -14%, 286%, 515%, 529%, 650%, 487%, 
501%, 258% and 258% for PID 6, 9, 13, 17, 21, 24, 31, 41 and 45 respectively. We did not observe 
significant difference in cold hypersensitivity between the left and right hindpaws (data not shown). 
Therefore, we pooled the thresholds from both hindpaws. The statistical analysis revealed 
significant effects of treatments, times and the interaction between treatments and times on hindpaw 
cold hypersensitivity development (for treatment: P=0.0001, df=1, F=1212.65; for time: P=0.0001, 
df=9, F=16.95; for interaction between treatment and time: P=0.0001, df=9, F=17.28). 
 
Indinavir treatment does not induce heat hypersensitivity 
We next tested if indinavir treatment results in changes in heat sensitivity. In contrast to the 
development of hindpaw mechanical and cold hypersensitivity following indinavir treatment, we 
did not observe increased hindpaw responses to noxious thermal stimuli using the Hargreaves’s 
device in indinavir-treated animals (n=6) as compared to the baseline and that of the vehicle-treated 
animals (n=6) (Figure 3). The statistical analysis revealed no significant effects of treatments, times 
and the interaction between treatments and times on hindpaw heat hypersensitivity development 
(for treatment: P=0.474, df=1, F=0.554; for time: P=0.935, df=5, F=0.255; for interaction between 
treatment and time: P=0.911, df=5, F=0.299). 
 
Thigmotaxis was increased following indinavir treatment  
An open field apparatus was used to assess the impact of indinavir treatment on thigmotactic 
behaviour. Such behaviour has been previously shown to be associated with pain behaviour in 
animal models of nerve trauma, varicella zoster virus, HIV gp120, and antiretroviral drugs [15; 17; 
49-52]. Here we showed that animals treated with indinavir (n=8) established hindpaw mechanical 
hypersensitivity at PID 14 (Indinavir: baseline=44.6±0.7 vs PID 14=25.8±0.6, P<0.05; Vehicle: 
baseline=45.5±0.6 vs PID 14=45.3±0.7, P>0.05). Then at PID 15 we showed a significant treatment 
effect on thigmotaxis behaviour using statistical analysis (P=0.021, df=2, F=4.671). Thus, at PID 
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15, track pattern analysis using entry number and time spent in the virtual inner zone demonstrated 
a significant effect of indinavir on spontaneous explorations. Animals received indinavir treatment 
had much lower number of entry (4.0±1.3) and less time spent (5.0±1.7 s) in the virtual zone in 
contrast to the naïve (n=8, 11.4±1.7 and 12.8±1.9 s; P<0.05, ANOVA/Tukey-Kramer post hoc test) 
and vehicle-treated (n=8, 10.5±1.9 and 11.4±1.5 s; P<0.05, ANOVA/Tukey-Kramer post hoc test) 
animals (Figure 4). We did not observe any difference in the total distance travelled in the open 
field among the groups at PID 15 (indinavir 7326.5±12.8cm vs naïve 7602.1±23.6 or vehicle 
7513.9±18.5cm, P>0.05), which is in line with our previous data [17; 49; 50]. 
 
Effects of analgesic drugs on hindpaw hypersensitivity  
We examined the pharmacological validity of our model using analgesic drugs, which have been 
shown either effective or not effective in the clinic for treating HIV-SN [41]. First we demonstrated 
that amitriptyline was not effective in reversing hindpaw mechanical hypersensitivity in animals 
treated with indinavir (Figure 5). The statistical analysis revealed no significant effects of 
treatments (amitriptyline/saline), times and the interaction between treatments and times on 
hindpaw mechanical hypersensitivity development (for treatment: P=0.179, df=1, F=2.087; for 
time: P=0.201, df=3, F=1.875; for interaction between treatment and time: P=0.538, df=3, 
F=0.738). In contrast systemic administration of gabapentin (Figure 5) was associated with a 
complete attenuation of hindpaw mechanical hypersensitivity observed with indinavir treatment. 
The statistical analysis revealed significant effects of treatments (gabapentin/saline), times and the 
interaction between treatments and times on hindpaw mechanical hypersensitivity (for treatment: 
P=0.0001, df=1, F=14486.08; for time: P=0.002, df=3, F=6.395; for interaction between treatment 
and time: P=0.0001, df=3, F=29.05). We did not observe any effects of vehicle administration. By 
PID 18, hindpaw mechanical hypersensitivity was re-established in the gabapentin group, 
suggesting a return of the neuropathic state. 
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Indinavir treatment results in reduced epidermal innervation of hindpaw skin 
We applied PGP 9.5 immunostaining to visualise unmyelinated fibres in the hindpaw skin. 
Following indinavir treatment (n=6) at PID 14, there was a significant reduction in intraepidermal 
nerve fibre density (IENFD) suggesting a withdrawal of unmyelinated axons from the epidermis 
when compared to that of the vehicle-treated animals (n=6) (Wilcoxon-Mann-Whitney Test, 
P=0.02; Figure 6). 
 
Systemic indinavir induces a minimal spinal microglial response and no inflammatory cell 
response in the DRG  
We examined if a glial cell response in the dorsal horn could be induced by systemic treatment of 
indinavir. We stained L5 sections with the microglial marker Iba1, and then counted the number of 
cells in the superficial dorsal horn exhibiting “effector” morphology, i.e. cell body hypertrophy and 
process retraction. We found that indinavir-treated rats had significantly increased numbers of 
microglia with “effector” morphology (indinavir: 7.66±0.61 vs vehicle: 2.80±0.31 cells per 50,000 
m2, n=5 per group, P=0.0001, Wilcoxon-Mann-Whitney Test; Figure 7). There appeared no 
difference in Iba1 immunoreactivity in other areas of the spinal cord (Supplementary Figures 1 and 
2). Then we assessed microglial activation by looking at pp-38 expression. Double immunostaining 
showed a significant increase in the number of microglia positive for pp-38 in animals treated with 
indinavir in comparison to the controls at PID 14 (indinavir: 41.41±7.68% vs vehicle: 6.65±2.15%; 
n=5, Wilcoxon-Mann-Whitney Test, P=0.008; Figure 8). The level of this increase is much less in 
contrast to that following spinal nerve ligation (Figure 8). We also investigated the astrocytic 
response to indinavir and found that there was no difference in GFAP immunoreactivity in the 
dorsal horn between the indinavir-treated and control groups at PID 14 (indinavir 91.39±14.27 vs 
vehicle 100.00±14.42, n=5 per group, P=0.68, Wilcoxon-Mann-Whitney Test; Figure 7). Nerve 
injury recruits macrophages into the DRG. Therefore, we examined if such macrophage infiltration 
accompanied the painful peripheral neuropathy induced by indinavir treatment. We found that the 
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number of Iba-1 immunoreactive cells in L5 DRG did not increase following indinavir treatment 
(n=5, vehicle 6.5±0.45 vs indinavir 7.52±0.97, P=0.36, Wilcoxon-Mann-Whitney Test; Figure 9). 
 
Systemic indinavir does not alter IB4 and CGRP expression of lumbar spinal cord and DRG 
We examined the expression of neurochemical markers for different DRG cell populations 
following indinavir treatment. Nonpeptidergic and peptidergic small-diameter DRG cells can be 
labelled with IB4 and CGRP respectively. After nerve trauma, the two markers are down-regulated. 
In contrast, here we found no change in the percentages of IB4+ DRG cells and CGRP+ DRG cells 
following indinavir treatment in the lumber spinal cord (n=5, IB4: vehicle 100.00±8.12% vs 
indinavir 108.55±13.51%, P=0.75, CGRP: vehicle 100.00±12.13% vs indinavir 90.34±19.15%, 
P=0.47, Wilcoxon-Mann-Whitney Test in both cases; Figure 7). A similar finding was found in the 
lumber DRG (n=5, IB4: vehicle 33.62±1.13% vs indinavir 33.98±0.50%, P=0.76, CGRP: vehicle 
31.52±1.05% vs indinavir 31.82±1.19%, P=0.86, Wilcoxon-Mann-Whitney Test in both cases; 
Figure 9). 
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Discussion  
 
Pharmacological agents such as drugs inhibit the protease activity of HIV (e.g. indinavir) are key 
components of drug therapy for HIV patients. However, limited clinical observations and one in 
vitro study suggest that indinavir exposure might increase the risk for HIV-SN [11; 29; 39; 41; 46]. 
We, and others, have previously extensively described the neurotoxicity associated with the d-NTRI 
group of antiretroviral drugs. However, we are the first who have comprehensively documented in 
vivo the neurotoxicity associated with wholly different class of antiretroviral drugs, the protease 
inhibitors, which were hitherto hinted at the above mentioned limited evidence, but in the main 
were not suspected of being neurotoxic. Our study provides the first in vivo evidence of an indinavir 
induced peripheral neuropathy in a rodent model. Here, we have shown a persistent painful 
peripheral sensory neuropathy developed in indinavir-treated animals that had no motor deficits, 
resembling a major clinical problem in HIV management. In accordance with the clinical 
presentation, we have shown not only simple reflex pain behaviour, which was sensitive to 
pharmacological perturbation, but also a complex thigmotactic behaviour associated with pain. 
Furthermore, we have shown, using histology, that our model is characterised by a retraction of 
epidermal axons, which is an established clinical diagnostic technique for HIV-SN [42] and other 
peripheral neuropathies that have a small fibre component [26; 34]. We have also demonstrated a 
small but significant microglial response in indinavir-treated animals at the time of peak hindpaw 
mechanical hypersensitivity. Prominently, this neurotoxicity seen in our model happens 
independently of HIV infection. The latter is a difficult confound to dissect in patients, because not 
only the two conditions co-exist, but also HIV and sensory neurons interaction can cause painful 
neuropathy [40; 50]. 
 
Here we have observed both mechanical and cold, but not heat, hypersensitivity in the hindpaws of 
indinavir-treated animals, contrasting to animal models of NRTIs-induced peripheral neuropathy, 
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which shows only hindpaw mechanical hypersensitivity [17; 19; 50]. This finding is also in contrast 
with early clinical data showing that patients with HIV-related painful neuropathy do not usually 
present with thermal hypersensitivity [33]. Our recent study involving a cohort of HIV-infected 
patients with and without HIV-SN, most of whom had received combinational ART including 
indinavir, has shown that the most frequent sensory abnormalities demonstrated in the HIV-SN 
group are loss of mechanical and vibration detection thresholds followed by a significant loss of 
cold and warm detection thresholds and heat pain threshold when compared to those of neuropathy 
free HIV positive patients and healthy volunteers, demonstrated by quantitative sensory testing [40]. 
The same study has also shown that whilst the presence of gain-of-sensory function is rare across all 
groups, a small minority of patients has features of mechanical wind-up ratio in HIV-SN patients. 
Subgroup analysis of a randomized controlled trial of pregabalin in HIV-SN has reported a small 
group of patients with signs of mechanical sensory gain [44]. Furthermore, by using the 
Neuropathic Pain Symptom Inventory it has been revealed that 42% of participants experiencing 
painful HIV-SN report symptoms of moderate and severe cold evoked pain, although this is not 
detected with sensory profiling [40]. Here, we have shown that indinavir-treated rats display 
increased thigmotaxis in the open field at the time of peak hindpaw mechanical hypersensitivity. 
This suggests the presence of pain-driven alterations in affect, which may be representative of 
ongoing pain and/or pain-related affective co-morbidities, which are known to be a feature of 
neuropathic pain in humans [14; 35; 36]. Indeed, our recent study has shown that participants with 
painful HIV-SN have reduced quality of life, a higher incidence of insomnia, and increased 
depression, anxiety, and catastrophizing, when compared to participants without HIV-SN [40].  
 
Previously it has been shown that in cultures of CD4 and CCR5 expressing rat DRG neurons 
infected with HIV-1 with subsequent treatment by indinavir, there is a marked reduction of neurites 
numbers and lengths, suggesting additive neurotoxic effects by indinavir [39]. Indinavir-treated 
DRG cultures also showed numerous TUNEL (an apoptosis marker)-positive nuclei in cells that 
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were ED-1 (a macrophage marker) immunoreactive, suggesting that resident DRG macrophages 
may be targets of indinavir toxicity. In the current study no DRG abnormalities were observed 
following indinavir administration, i.e. no change in CGRP+ or IB4+ neurons or in macrophage 
infiltration, which markedly contrasts to nerve trauma models. Furthermore, no changes were found 
in the central projections of primary afferents after indinavir treatment. Thus, we did not observe 
reduced CGRP expression and IB4 binding in L5 dorsal horn, where primary afferents from 
hindpaws end. This finding is in contrast to significant reductions in CGRP/IB4 immunoreactivity 
in L5 spinal dorsal horn seen in animals treated with d4T [17].  Activation of the innate immune 
system in the dorsal horn of the spinal cord is key in the development of pain after nerve injury [2; 
6]. However in the case of indinavir treatment we only observed a small but significant increase 
(1.7 folds) in microgliosis; we observed an increased microglial expression of pp-38, which is 
known to promote the microglial proinflammatory responses to produce mediators such as COX-2, 
IL-1β, BDNF and iNOS, contributing to neuropathic pain development and maintenance [6]. We 
did not observe any evidence of astrocyte response to indinavir treatment. Our observation of a 
minimal glial and immune response in the spinal cord and DRG following indinavir treatment is 
comparable to those reported in chemotherapy or metabolic agents induced chronic painful 
neuropathy [4; 6; 17; 53], highlighting the need for relevant animal models to address particular 
clinical scenarios. 
 
Importantly here indinavir administration resulted in a reduction in hindpaw IENFD, which is also 
manifested in many other painful neuropathies [27], such as SN resulted from ddC [50] and d4T 
[17] treatment, and direct neurotoxicity mediated by HIV virus [49]. Reduced IENFD, a key clinical 
diagnostic tool for HIV-SN, correlates inversely with neuropathic pain progress [40; 42]. There is 
evidence suggesting that protease inhibitors are associated with insulin resistance and resultant 
diabetic complications in HIV patients [7], which is thought to be mediated through the inhibition 
of insulin-regulated glucose transporter [10]. Therefore, it is possible that such diabetic 
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complications could also result in the development of diabetic peripheral sensory neuropathy with a 
characteristic loss of IENFD on skin biopsy [37]. In the current study, we found no significant 
difference in blood glucose levels and body weights at PID 19 and PID 45 between indinavir-
treated and vehicle-treated animals (data not shown), suggesting that the dose regime of indinavir in 
our study did not cause insulin resistance.  
 
Our study could explain the well-documented persistence of painful peripheral neuropathy in 
patients who have not been exposed to d-NRTIs or who were not susceptible to d-NRTI-
neurotoxicity, which had hitherto been assumed to be the main cause of neurotoxicity. Our study 
also highlights the importance of using animal models to study cause of the neurotoxicity of 
protease inhibitors in isolation, since there are too many confounds in patients because they have 
concomitant HIV disease and also take a plethora of other drugs, including a combination 
antiretroviral drugs. We chose to explore indinavir, one of the prototypical protease inhibitors, as it 
is representative of the class. However, we acknowledge that in well-resourced settings it has been 
replaced by new generation protease inhibitors, and it has also been replaced by other protease 
inhibitors on the World Health Organization's List of Essential Medicines. However, there is still a 
huge clinical legacy of patients who had been exposed to it and who have persistent peripheral 
neuropathy that requires clinical management. We do not know whether the neurotoxicity which we 
demonstrated as being associated with indinavir is a PI class effect or unique to indinavir - that is 
for further studies. Here we have not studied the dose effect for indinavir, as the purpose of this 
report is to test whether indinavir can produce neurotoxicity in isolation rather than mimic the 
patient living with HIV. The dose of 50 mg/kg was chosen to keep consistency with our previous 
ddC and d4T studies and is likely to under estimate the human dose if converted using surface area 
dosage conversion. However, we agree that a dose effect study is important to expand the testing of 
our hypothesis and will be included in future studies along with ddC and d4T. We also agree that 
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electron microscopy studies might be useful in yielding further information, but are outside the 
scope of the current study. 
 
In summary, we have established a rodent model of painful SN mediated by systemic indinavir 
treatment. Our model mimics a number of clinical features and reveals important mechanistic 
differences when compared to the previously reported d4T model (Table 1). HIV-SN continues to 
be one of the most prevalent morbidities experienced by people living with HIV in both high- and 
low-resource settings. Our model offers an important tool to better comprehend the pathogenesis, 
develop preventive strategies, and discover effective drugs for HIV-SN. 
(Word count = 1469) 
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Figure Captions 
 
Figure 1: The development of hindpaw hypersensitivity to punctate mechanical stimuli 
following indinavir treatment. We measured the withdrawal thresholds at the baseline (BL) 
and after indinavir (50 mg/kg, twice at 4 days apart) or vehicle administration. Two-way 
ANOVA with Tukey-Kramer post hoc multiple comparisons were used to determine the 
difference between treatment groups. Asterisk=significant difference from the vehicle group 
(P<0.05); ‡=significant difference from the baseline (P<0.05).  
 
Figure 2: The development of hindpaw hypersensitivity to cold stimuli following 
indinavir treatment. We measured withdrawal responses at the baseline (BL) and after 
indinavir (50 mg/kg, twice at 4 days apart) or vehicle administration using an acetone drop. 
Two-way ANOVA with Tukey-Kramer post hoc multiple comparisons were used to 
determine the difference between treatment groups. Asterisk=significant difference from the 
vehicle group (P<0.05); ‡=significant difference from the baseline (P<0.05). 
 
Figure 3: No hindpaw hypersensitivity to thermal stimuli following indinavir treatment. 
We measured withdrawal responses at the baseline (BL) and after indinavir (50 mg/kg, twice 
at 4 days apart) or vehicle administration using a noxious thermal stimulus (Hargreaves’s 
device). Two-way ANOVA with Tukey-Kramer post hoc multiple comparisons were used to 
determine the difference between treatment groups. Asterisk=significant difference from the 
vehicle group (P<0.05); ‡=significant difference from the baseline (P<0.05). 
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Figure 4: Thigmotactic changes in the open field arena following indinavir treatment at 
PID 15. (A) Virtual inner zone (dotted square in C, 40 x 40 cm2) entry number and (B) the 
time spent in the virtual inner zone were assessed in the naïve, vehicle-treated, and indinavir-
treated (50 mg/kg, i.v., twice at 4 days apart) animals. (C) Illustration of movement of (i) 
naive, (ii) vehicle-treated, and (iii) indinavir-treated animals in the arena. The statistical 
significance of differences between the indinavir group and its relevant control (*P<0.05) was 
determined by a one-way ANOVA with Tukey-Kramer post hoc multiple comparisons. (A-B) 
Data were displayed using box and scatter plots. Each box represents mean±SEM. Bars above 
and below each box represents standard deviations. The line and the circle within the box 
represents median and mean respectively.  
 
Figure 5: The effect of analgesic drugs on hindpaw mechanical hypersensitivity. (A: 
gabapentin; B: amitriptyline) The effects of drugs administered around peak change in 
hindpaw sensitivity to mechanical stimuli in animals received indinavir treatment. 
Withdrawal thresholds (g) are displayed as prior, during and post each drug treatment (open 
circle) versus vehicle (filled triangle). A shaded area is used to show drug treatment period. 
Arrows and arrowheads represent the start and end of drug administration respectively. Two-
way ANOVA with Tukey-Kramer post hoc multiple comparisons were used to determine the 
difference between drug and vehicle threshold values. *P<0.05 vs vehicle. 
 
Figure 6: Reduced IENFD following indinavir treatment at PID 14. (a) An example of 
PGP9.5 stained skin sections of a vehicle animal. (b) An example of PGP9.5 stained skin 
sections of indinavir-treated animal. Following indinavir treatment, there is a significant 
reduction in intraepidermal fibre numbers (Wilcoxon-Mann-Whitney Test, P=0.02), which is 
demonstrated in the quantitative analysis of IENFD in (c). Scale bar=100 µm. 
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Figure 7. Systemic indinavir treatment induced microgliosis, but not astrogliosis and 
changes in IB4 and CGRP expressions, in the lumbar spinal cord at PID 14. (a, b) CGRP 
expression (green) in laminae I and IIo of L5 dorsal horns. (d, e) IB4 labelling (red) within 
lamina Iii of L5 dorsal horns. (c, f) Quantitative analyses showing no IB4 and CGRP 
alterations in L5 dorsal horns between vehicle and indinavir animals. (g, h) GFAP expression 
in astrocytes in L5 dorsal horns. (i) Quantitative analysis showing no change in GFAP 
expression in L5 dorsal horns between vehicle and indinavir animals. Indinavir treatment 
significantly increased the number of microglia with effector morphology (k, l) compared to 
the vehicle (j). **P<0.01. N=5 per group. Scale bars=200 m for top two rows (a, b, d, & e); 
50 m for the third row (g & h) and for the bottom row (j & k). 
 
Figure 8: Systemic indinavir treatment increased the level of expression of phospho-p38 
in spinal cord microglia. Phospho-p38 (green; e.g. e) is expressed by Iba1 positive spinal 
microglia (red; e.g. d) within the dorsal horn. This expression is significantly increased at PID 
14 following indinavir treatment (50 mg/kg, twice at 4 days apart) (d, e, f) compared to 
vehicle treatment (a, b, c). N=5 per group. For comparison, the normally observed increase in 
the proportion of microglia that are immunoreactive for phospho-p38 following SNL is shown 
in (g). **P<0.01 vs vehicle. Scale bar=50 μm. 
 
Figure 9. Systemic indinavir treatment did not induce neurochemical changes in sensory 
neurons and macrophage infiltration in L5 DRGs at PID 14. IB4 binding (red) and CGRP 
expression CGRP (green) were not changed following indinavir treatment (b, e) vs vehicle (a, 
d), and this was quantified in (c, f). Iba1 immunostaining was used as a marker of 
macrophages in L5 DRGs following vehicle (g) or indinavir (h) treatment. There was no 
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change in macrophage numbers in the DRG (quantified in i) following indinavir treatment. 
N=5 per group. Scale bars=50 m for top row (a & b), mid row (d & e), and bottom row (g & 
h). 
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Summary 
Rats treated with HIV antiretroviral drug indinavir demonstrated alterations in neuropathic pain-
related sensory and thigmotactic behaviours accompanied by significant loss of hindpaw skin sensory 
innervation. 
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Table 1. Comparison of key neurochemical markers in the lumbar spinal cord and DRG 
between indinavir and d4T models at the time of peak hindpaw mechanical hypersensitivity. 
 Indinavir model D4T model 
Spinal cord dorsal horn   
IB4 and CGRP expression No change Significant reduced in the 
medial portion 
Microglia with effector 
morphology 
A small but significant increase A small but significant increase 
Phospho-p38 expression in 
microglia 
A significant increase No change 
Astrocytes No change No change 
   
DRG   
IB4 and CGRP expression No change No change 
Macrophages No change No change 
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Supplementary materials 
 
1. Supplementary Table 1. Major domains of good laboratory practice to minimise the effects of 
experimental bias. 
 
 Description of procedures 
Sample Size 
Calculation 
 Group size was determined by sample size estimation for each 
experiment using SigmaStat Version 3.5 (ANOVA sample size, 
desired power = 0.8, alpha = 0.05).  
 Effect sizes for estimation were derived from previous studies in 
our group [1-3].  
Inclusion and 
Exclusion Criteria 
 In experiments for pharmacological validation and thigmotaxis, 
only rats that developed hindpaw mechanical hypersensitivity of at 
least 25% change from the baseline were included.  
Randomization  In experiments for mechanical, cold and heat hypersensitivity 
development and pharmacological studies, animals were 
randomized into treatment* groups by picking numbers out of a hat.  
 In experiments for thigmotaxis, random cage assignment to 
treatments was applied by picking numbers out of a hat.  
Allocation 
Concealment 
 The person creating the model (i.e. injection of indinavir or vehicle 
solution, administration of analgesic agent or vehicle solution) was 
unaware of the allocation to treatment group.  
 This was achieved by the blinding procedure described below, as 
well as masking cage labels or turning around the cages before each 
Supplementary Materials: figures, tables Click here to download Supplementary Materials: figures,
tables Indinavir_Suppl Materials_revision final.doc
2 
 
behavioural assessment session. 
Reporting of 
Animals 
Excluded From 
Analysis 
 Any rat showing hunched posture, a marked behavioural change, 
exudates around wound or sensitivity to palpitation on handling that 
could be attributable to surgery, the drug, the dosing procedure, 
infection resulting from surgery or otherwise, was excluded. 
 The details of the number of excluded animals and the reason for 
exclusion are stated in the results section. 
Blinded 
Measurement, 
Assessment, and 
Analysis of 
Outcome 
 Codes were assigned to different treatments by an independent 
person and kept in a sealed envelope. The codes were not broken 
until the analysis had been completed. 
 The experimenter was ‘blinded’ to the treatments received and had 
no knowledge of the experimental group to which an animal was 
randomized.  
*Treatment here refers to drug administration, i.e. indinavir versus vehicle, and each 
pharmacological analgesic agent versus vehicle. 
 
2. Supplementary Table 2. Details of groups and primary outcomes for behavioural experiments. 
 
 Group names Group 
sizes 
Primary outcomes 
MH development  Indinavir/vehicle 6/6 HPW threshold in response to punctate 
static mechanical stimulus 
CH development  
Indinavir/vehicle 
 
6/6 
HPW threshold in response to cold 
stimulus 
HH development HPW threshold in response to heat 
stimulus 
Thigmotaxis Indinavir/vehicle/naive 8/8/8 Frequency of entry and duration in the 
inner zone 
Pharmacological 
validation 
Gabapentin/vehicle 6/6 HPW threshold in response to punctate 
static mechanical stimulus 
Amitriptyline/vehicle 6/6 HPW threshold in response to punctate 
static mechanical stimulus 
 
MH = mechanical hypersensitivity;  
CH = cold hypersensitivity; 
HH = heat hypersensitivity; 
HPW = hindpaw withdrawal 
 
3 
 
3. Supplementary Table 3. Behavioural data presented with mean and 95% confidence levels (CI). 
 Vehicle Indinavir 
MH development Mean 95% CI Mean 95%CI 
Baseline 44.8 44.2, 45.5 45.3 44.3, 46.4 
PID 4 45.7 43.8, 47.6 33.8 32.8, 34.7 
PID 7 46.4 44.8, 48.0 30.5 28.3, 32.8 
PID11 44.2 43.2, 45.2 27.6 27.0, 28.1 
PID 14 44.2 43.6, 44.7 25.4 24.6, 26.1 
PID 28 44.9 43.2, 46.6 28.9 27.9, 29.9 
PID 35 45.1 43.7, 46.5 33.7 32.2, 35.2 
PID 42 45.4 43.8, 46.9 41.9 41.2, 42.6 
     
CH development Mean 95% CI Mean 95%CI 
Baseline 0.1 0.0, 0.0 0.1 0.1, 0.1 
PID 6 0.1 0.0, 0.0 0.1 0.1, 0.1 
PID 9 0.1 0.0, 0.0 0.5 0.3, 0.6 
PID13 0.1 0.1, 0.1 0.7 0.7, 0.8 
PID 11 0.0 0.0, 0.0 0.7 0.7, 0.8 
PID 21 0.0 0.0, 0.0 0.8 0.7, 0.8 
PID 24 0.1 0.0, 0.0 0.7 0.6, 0.8 
PID 31 0.1 0.0, 0.0 0.7 0.6, 0.8 
PID 41 0.1 0.0, 0.0 0.4 0.2, 0.6 
PID 45 0.1 0.0, 0.0 0.4 0.3, 0.6 
     
HH development Mean 95% CI Mean 95%CI 
Baseline 11.1 10.1, 12.0 10.8 10.0, 11.7 
PID 6 11.2 10.9, 11.5 10.6 10.0, 11.2 
PID 9 11.3 10.8, 11.9 10.6 10.0, 11.1 
PID13 11.2 10.7, 11.6 10.7 10.5, 10.8 
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PID 11 11.5 10.9, 12.0 10.7 10.4, 11.0 
PID 21 11.4 11.2, 11.6 10.8 10.5, 11.2 
     
 Saline Gabapentin 
MH Mean 95% CI Mean 95%CI 
Day 12 22.7 22.0, 23.4 42.5 41.4, 43.6 
Day 13 19.8 18.8, 20.8 45.4 44.9, 45.9 
Day 14 17.4 16.5, 18.3 44.3 43.1, 45.6 
Day 15 18.3 16.8, 19.7 45.6 44.2, 47.0 
     
 Saline Amitriptyline 
MH Mean 95% CI Mean 95%CI 
Day 12 21.8 21.2, 22.3 22.5 21.7, 23.4 
Day 13 19.9 19.4, 20.4 20.5 20.0, 21.0 
Day 14 19.9 18.9, 20.9 20.2 19.4, 20.9 
Day 15 20.6 20.0, 21.2 20.3 19.5, 21.1 
     
 Vehicle Indinavir 
MH-thigmotaxis Mean 95% CI Mean 95%CI 
Baseline 45.8 45.0, 46.5 44.8 44.0, 45.6 
PID 14 45.7 44.5, 47.0 25.6 24.6, 26.6 
     
 Duration (second) Entry number 
Thigmotaxis Mean 95% CI Mean 95%CI 
Naive 15.3 11.5, 19.0 13.3 9.6, 17.1 
Vehicle-treated 12.9 9.4, 16.3 12.5 8.2, 16.8 
Indinavir-treated 5.3 0.7, 9.8 4.0 0.7, 7.3 
MH = mechanical hypersensitivity;  
CH = cold hypersensitivity; 
HH = heat hypersensitivity; 
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3. Supplementary Figure 1. Iba1 staining of the lumbar spinal cord from vehicle-treated 
animals at low (10x) objective magnification. (a-e), example images of Iba1 staining of transverse 
sections of the L5 spinal cord from 5 animals. Scale bar=100μm. 
 
 
4. Supplementary Figure 2. Iba1 staining of the lumbar spinal cord from indinavir-treated 
animals at low (10x) objective magnification. (a-e), example images of Iba1 staining of transverse 
sections of the L5 spinal cord from 5 animals. Scale bar=100μm. 
 
6 
 
References: 
[1] Huang W, Calvo M, Karu K, Olausen HR, Bathgate G, Okuse K, Bennett DL, Rice AS. A 
clinically relevant rodent model of the HIV antiretroviral drug stavudine induced 
painful peripheral neuropathy. Pain 2013;154(4):560-575. 
[2] Wallace VCJ, Blackbeard J, Pheby T, Segerdahl AR, Davies M, Hasnie F, Hall S, 
McMahon SB, Rice ASC. Pharmacological, behavioural and mechanistic analysis of 
HIV-1 gp120 induced painful neuropathy. Pain 2007;133(1-3):47-63. 
[3] Wallace VCJ, Blackbeard J, Segerdahl AR, Hasnie F, Pheby T, McMahon SB, Rice ASC. 
Characterization of rodent models of HIV-gp120 and anti-retroviral-associated 
neuropathic pain. Brain 2007;130(10):2688-2702. 
 
  
The ARRIVE Guidelines Checklist 
Animal Research: Reporting In Vivo Experiments 
Carol Kilkenny1, William J Browne2, Innes C Cuthill3, Michael Emerson4 and Douglas G Altman5 
1The National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, UK, 2School of Veterinary 
Science, University of Bristol, Bristol, UK, 3School of Biological Sciences, University of Bristol, Bristol, UK, 4National Heart and Lung 
Institute, Imperial College London, UK, 5Centre for Statistics in Medicine, University of Oxford, Oxford, UK. 
 
 ITEM RECOMMENDATION Section/ Paragraph 
Title 1 Provide as accurate and concise a description of the content of the article 
as possible. 
      
Abstract 2 Provide an accurate summary of the background, research objectives, 
including details of the species or strain of animal used, key methods, 
principal findings and conclusions of the study. 
      
INTRODUCTION  
Background 3 a. Include sufficient scientific background (including relevant references to 
previous work) to understand the motivation and context for the study, 
and explain the experimental approach and rationale. 
b. Explain how and why the animal species and model being used can 
address the scientific objectives and, where appropriate, the study’s 
relevance to human biology. 
      
Objectives 4 Clearly describe the primary and any secondary objectives of the study, or 
specific hypotheses being tested. 
      
METHODS  
Ethical statement 5 Indicate the nature of the ethical review permissions, relevant licences (e.g. 
Animal [Scientific Procedures] Act 1986), and national or institutional 
guidelines for the care and use of animals, that cover the research. 
      
Study design 6 For each experiment, give brief details of the study design including: 
a. The number of experimental and control groups. 
b. Any steps taken to minimise the effects of subjective bias when 
allocating animals to treatment (e.g. randomisation procedure) and when 
assessing results (e.g. if done, describe who was blinded and when). 
c. The experimental unit (e.g. a single animal, group or cage of animals). 
A time-line diagram or flow chart can be useful to illustrate how complex 
study designs were carried out. 
      
Experimental 
procedures 
7 For each experiment and each experimental group, including controls, 
provide precise details of all procedures carried out. For example: 
a. How (e.g. drug formulation and dose, site and route of administration, 
anaesthesia and analgesia used [including monitoring], surgical 
procedure, method of euthanasia). Provide details of any specialist 
equipment used, including supplier(s). 
b. When (e.g. time of day). 
c. Where (e.g. home cage, laboratory, water maze). 
d. Why (e.g. rationale for choice of specific anaesthetic, route of 
administration, drug dose used). 
      
Experimental 
animals 
8 a. Provide details of the animals used, including species, strain, sex, 
developmental stage (e.g. mean or median age plus age range) and 
weight (e.g. mean or median weight plus weight range). 
b. Provide further relevant information such as the source of animals, 
international strain nomenclature, genetic modification status (e.g. 
knock-out or transgenic), genotype, health/immune status, drug or test 
naïve, previous procedures, etc. 
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 Housing and 
husbandry 
9 Provide details of: 
a. Housing (type of facility e.g. specific pathogen free [SPF]; type of cage or 
housing; bedding material; number of cage companions; tank shape and 
material etc. for fish). 
b. Husbandry conditions (e.g. breeding programme, light/dark cycle, 
temperature, quality of water etc for fish, type of food, access to food 
and water, environmental enrichment). 
c. Welfare-related assessments and interventions that were carried out 
prior to, during, or after the experiment. 
      
Sample size 10 a. Specify the total number of animals used in each experiment, and the 
number of animals in each experimental group.  
b. Explain how the number of animals was arrived at. Provide details of any 
sample size calculation used. 
c. Indicate the number of independent replications of each experiment, if 
relevant. 
      
Allocating 
animals to 
experimental 
groups 
11 a. Give full details of how animals were allocated to experimental groups, 
including randomisation or matching if done. 
b. Describe the order in which the animals in the different experimental 
groups were treated and assessed. 
      
Experimental 
outcomes 
12 Clearly define the primary and secondary experimental outcomes assessed 
(e.g. cell death, molecular markers, behavioural changes). 
      
Statistical 
methods 
13 a. Provide details of the statistical methods used for each analysis. 
b. Specify the unit of analysis for each dataset (e.g. single animal, group of 
animals, single neuron). 
c. Describe any methods used to assess whether the data met the 
assumptions of the statistical approach. 
      
RESULTS  
Baseline data 14 For each experimental group, report relevant characteristics and health 
status of animals (e.g. weight, microbiological status, and drug or test naïve) 
prior to treatment or testing. (This information can often be tabulated). 
      
Numbers 
analysed 
15 a. Report the number of animals in each group included in each analysis. 
Report absolute numbers (e.g. 10/20, not 50%2). 
b. If any animals or data were not included in the analysis, explain why. 
      
Outcomes and 
estimation 
16 Report the results for each analysis carried out, with a measure of precision 
(e.g. standard error or confidence interval). 
      
Adverse events 17 a. Give details of all important adverse events in each experimental group. 
b. Describe any modifications to the experimental protocols made to 
reduce adverse events. 
      
DISCUSSION  
Interpretation/ 
scientific 
implications 
18 a. Interpret the results, taking into account the study objectives and 
hypotheses, current theory and other relevant studies in the literature. 
b. Comment on the study limitations including any potential sources of bias, 
any limitations of the animal model, and the imprecision associated with 
the results2. 
c. Describe any implications of your experimental methods or findings for 
the replacement, refinement or reduction (the 3Rs) of the use of animals 
in research. 
      
Generalisability/ 
translation 
19 Comment on whether, and how, the findings of this study are likely to 
translate to other species or systems, including any relevance to human 
biology. 
      
Funding 20 List all funding sources (including grant number) and the role of the 
funder(s) in the study. 
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